Calcitonin inhalation - Otsuka Pharmaceutical

Drug Profile

Calcitonin inhalation - Otsuka Pharmaceutical

Alternative Names: Calcitonin ODPI - Otsuka Pharmaceutical; OPC-246; OPC-249

Latest Information Update: 02 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Musculoskeletal pain

Most Recent Events

  • 20 Jul 2012 The European Medicines Agency recommended that due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
  • 26 Feb 2009 Inhaled calcitonin is still in phase II trials for pain due to osteoporosis (Musculoskeletal pain) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top